Literature DB >> 24690258

Protective effects of phosphodiesterase-1 (PDE1) and ATP sensitive potassium (KATP) channel modulators against 3-nitropropionic acid induced behavioral and biochemical toxicities in experimental Huntington׳s disease.

Surbhi Gupta1, Bhupesh Sharma2.   

Abstract

Huntington׳s disease (HD), a devastating neurodegenerative disorder, is characterized by weight loss, impairment of motor function, cognitive dysfunction, neuropsychiatric disturbances and striatal damage. Phosphodiesterase-1 (PDE1) has been implicated in various neurological diseases. Mitochondrial potassium channels in the brain take part in neuroprotection. This study has been structured to investigate the role of vinpocetine, a selective PDE1 inhibitor as well as nicorandil, selective ATP sensitive potassium (KATP) channel opener in 3-nitropropionic acid (3-NP) induced HD symptoms in rats. Systemic administration of 3-NP significantly, reduced body weight, impaired locomotion, grip strength and impaired cognition. 3-NP elicited marked oxidative stress in the brain (enhanced malondialdehyde-MDA, reduced glutathione-GSH content, superoxide dismutase-SOD and catalase-CAT), elevated brain acetylcholinesterase activity and inflammation (myeloperoxidase-MPO), with marked nitrosative stress (nitrite/nitrate) in the brain. 3-NP has also induced mitochondrial dysfunction (impaired mitochondrial NADH dehydrogenase-complex I, succinate dehydrogenase-complex II and cytochrome oxidase-complex IV) activities in the striatum of the rat. Tetrabenazine was used as a positive control. Treatment with vinpocetine, nicorandil and tetrabenazine ameliorated 3-NP induced reduction in body weight, impaired locomotion, grip strength and impaired cognition. Treatment with these drugs reduced brain striatum oxidative (MDA, GSH, SOD and CAT) and nitrosative (nitrite/nitrate) stress, acetylcholinesterase activity, inflammation and mitochondrial dysfunctions. These results indicate that vinpocetine, a selective PDE1 inhibitor and nicorandil, a KATP channel opener have attenuated 3-NP induced experimental HD. Hence, pharmacological modulation of PDE1 as well as KATP channels may be considered as potential research targets for mitigation of HD.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  3-Nitropropionic acid; Acetylcholinesterase; Mitochondrial enzyme complexes; Myeloperoxidase; Nicorandil; Vinpocetine

Mesh:

Substances:

Year:  2014        PMID: 24690258     DOI: 10.1016/j.ejphar.2014.03.032

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  [Nicorandil improves cognitive dysfunction in mice with streptozotocin-induced diabetes].

Authors:  Wen-Hui Yan; Chun-Xi Zhang; Tong Xing; Xue Gong; Yu-Xuan Yang; Yi-Nuo Li; Xuan Liu; Jiamaliding Ayijiang; Ye Yu; Meng Zhang; Li-Na Chen
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-04-20

Review 2.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

Review 3.  An update on vinpocetine: New discoveries and clinical implications.

Authors:  Yi-Shuai Zhang; Jian-Dong Li; Chen Yan
Journal:  Eur J Pharmacol       Date:  2017-11-26       Impact factor: 4.432

Review 4.  Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease.

Authors:  Antonella Cardinale; Francesca R Fusco
Journal:  CNS Neurosci Ther       Date:  2018-03-03       Impact factor: 5.243

5.  Protective effect of vinpocetine against neurotoxicity of manganese in adult male rats.

Authors:  Rania I Nadeem; Hebatalla I Ahmed; Bahia M El-Sayeh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-04-18       Impact factor: 3.000

Review 6.  Potassium channel dysfunction in neurons and astrocytes in Huntington's disease.

Authors:  Xiao Zhang; Jie-Qing Wan; Xiao-Ping Tong
Journal:  CNS Neurosci Ther       Date:  2018-01-27       Impact factor: 5.243

7.  Activating adenosine A1 receptor accelerates PC12 cell injury via ADORA1/PKC/KATP pathway after intermittent hypoxia exposure.

Authors:  Hong-Fang Mei; Neha Poonit; Yi-Chun Zhang; Chu-Yuan Ye; Hui-Lin Cai; Chen-Yi Yu; Yong-Hai Zhou; Bei-Bei Wu; Jun Cai; Xiao-Hong Cai
Journal:  Mol Cell Biochem       Date:  2018-01-29       Impact factor: 3.396

Review 8.  Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities.

Authors:  Arun Samidurai; Lei Xi; Anindita Das; Audra N Iness; Navin G Vigneshwar; Pin-Lan Li; Dinender K Singla; Sakthivel Muniyan; Surinder K Batra; Rakesh C Kukreja
Journal:  Pharmacol Ther       Date:  2021-04-22       Impact factor: 13.400

9.  Tert-buthylhydroquinone pre-conditioning exerts dual effects in old female rats exposed to 3-nitropropionic acid.

Authors:  Alejandro Silva-Palacios; Ana L Colín-González; Stefanie P López-Cervantes; Cecilia Zazueta; Armando Luna-López; Abel Santamaría; Mina Königsberg
Journal:  Redox Biol       Date:  2017-03-31       Impact factor: 11.799

Review 10.  Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale.

Authors:  Owen Sanders; Lekshmy Rajagopal
Journal:  J Alzheimers Dis Rep       Date:  2020-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.